Cargando…

A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood

GD2, a disialoganglioside, is present on the surface of most neuroblastomas, as well as on some other cancers, such as melanoma and osteogenic sarcoma. The anti-GD2 antibody ch14.18 (dinutuximab) has an FDA-registered indication for use as maintenance therapy for high-risk neuroblastoma with cytokin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keyel, Michelle E., Furr, Kathryn L., Kang, Min H., Reynolds, C. Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573805/ https://www.ncbi.nlm.nih.gov/pubmed/37834874 http://dx.doi.org/10.3390/jcm12196223

Ejemplares similares

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
por: Keyel, Michelle E, et al.
Publicado: (2018)

Dinutuximab beta for neuroblastoma
Publicado: (2020)

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
por: Ehlert, Karoline, et al.
Publicado: (2020)

Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
por: Spasov, Neofit, et al.
Publicado: (2021)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
por: Launspach, Michael, et al.
Publicado: (2021)

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
por: Cupit-Link, Margaret, et al.
Publicado: (2023)

Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry
por: El Amrani, Mohsin, et al.
Publicado: (2018)

Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
por: Mastrangelo, Stefano, et al.
Publicado: (2021)

Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma
por: Balaguer, Julia, et al.
Publicado: (2022)

An Adaptable Two-Color Flow Cytometric Assay to Quantitate the Invasion of Erythrocytes by Plasmodium falciparum Parasites
por: Theron, Michel, et al.
Publicado: (2010)

A flow cytometric assay to quantify invasion of red blood cells by rodent Plasmodium parasites in vivo
por: Lelliott, Patrick M, et al.
Publicado: (2014)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
por: Ornell, Kimberly J., et al.
Publicado: (2020)

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
por: Giljević, Jasminka Stepan, et al.
Publicado: (2022)

A multi-parametric flow cytometric assay to analyze DNA–protein interactions
por: Arbab, Mandana, et al.
Publicado: (2013)

Color atlas/text of flow cytometric analysis of hematologic neoplasms
por: Sun, Tsieh
Publicado: (1993)

Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance
por: Barone, Giuseppe, et al.
Publicado: (2021)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
por: Wieczorek, Aleksandra, et al.
Publicado: (2022)

Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava
por: Achbergerová, Monika, et al.
Publicado: (2022)

Assay for ADAMTS-13 Activity with Flow Cytometric Readout
por: Müller, Jens, et al.
Publicado: (2022)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
por: Cicek, Filiz, et al.
Publicado: (2020)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
por: Olgun, Nur, et al.
Publicado: (2022)

Quantifying Distribution of Flow Cytometric TCR-Vβ Usage with Economic Statistics
por: van der Geest, Kornelis S. M., et al.
Publicado: (2015)

Current Flow Cytometric Assays for the Screening and Diagnosis of Primary HLH
por: Chiang, Samuel Cern Cher, et al.
Publicado: (2019)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
por: Ladenstein, Ruth, et al.
Publicado: (2020)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Prediction of Therapy Response and Prognosis in Leukemias by Flow Cytometric MDR Assays
por: Kappelmayer, János, et al.
Publicado: (2013)

Antigen density quantification of cell-surface immunotherapy targets by flow cytometry: Multi-antigen assay of neuroblastoma bone marrow metastasis
por: Radosevich, Molly T., et al.
Publicado: (2023)

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Flow cytometric analysis of hematologic neoplasms : a color atlas & text /
por: Sun, Tsieh
Publicado: (2002)

Bead-Based Flow Cytometric Assays: A Multiplex Assay Platform with Applications in Diagnostic Microbiology
por: Ernst, David, et al.
Publicado: (2006)

The Efficiency of Color Space Channels to Quantify Color and Color Intensity Change in Liquids, pH Strips, and Lateral Flow Assays with Smartphones
por: Nelis, Joost Laurus Dinant, et al.
Publicado: (2019)

Protein A-Mediated Binding of Staphylococcus spp. to Antibodies in Flow Cytometric Assays and Reduction of This Binding by Using Fc Receptor Blocking Reagent
por: Cronin, Ultan P., et al.
Publicado: (2020)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
por: Flaadt, Tim, et al.
Publicado: (2023)

A novel flow cytometric assay for measurement of In Vivo pulmonary neutrophil phagocytosis
por: Vander Top, Elizabeth A, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ueracq8qcc4iftamesfdmmvtbt